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Abstract 16 
Hepatocellular carcinoma (HCC) carries a dismal prognosis, with advanced disease being resistant to 17 
both radiotherapy and conventional cytotoxic drugs, whilst anti-angiogenic drugs are marginally 18 
efficacious. Oncolytic viruses (OV) offer the promise of selective cancer therapy through direct and 19 
immune-mediated mechanisms. The premise of OV lies in their preferential genomic replication, 20 
protein expression and productive infection of malignant cells. Numerous oncolytic viruses are being 21 
tested in pre-clinical models of HCC, with good evidence of direct and immune-mediated anti-tumour 22 
efficacy. Efforts to enhance the performance of these agents have concentrated on engineering OV 23 
cellular specificity, immune evasion, enhancing anti-tumour potency and improving delivery. The 24 
lead agent in HCC clinical trials, JX-594, a recombinant Wyeth strain Vaccinia virus has 25 
demonstrated evidence for significant benefit and earned orphan drug status. Thus, JX-594 appears to 26 
be transcending the barrier between novel laboratory science and credible clinical therapy. Otherwise, 27 
relatively few other OV have entered clinical testing, a hurdle that must be overcome if significant 28 
progress is to be made in this field.  29 
This review summarises the pre-clinical and clinical experience of OV therapy in the difficult-to-treat 30 
area of HCC.  31 
Introduction 32 
HCC is a malignancy of hepatocytes with an annual incidence over 500,000 (Boyle et al., 2008). The 33 
majority of HCC cases can be attributed to defined environmental risks; worldwide, the proportion of 34 
HCC caused by chronic hepatitis B virus (HBV) infection is approximately 54%, with 31% being 35 
attributed to hepatitis C virus (HCV) (Boyle et al., 2008). A safe and effective vaccine exists for HBV 36 
with good global coverage ³:+2_,PPXQL]DWLRQFRYHUDJH´. In contrast, the highly 37 
heterogeneous nature of HCV has hampered attempts at vaccine development. In the UK, HCC 38 
caused by alcohol and non-alcohol-related fatty liver disease is on the rise (CRUK, 2013). The 39 
majority of patients present with advanced incurable disease and the overall 5 year survival rate is 40 
between 5 and 9% (Boyle et al., 2008). Early diagnosis is critical, as patients with localised HCC and 41 
a good performance status may be offered potentially curative liver resection or transplantation. The 42 
management of patients with advanced HCC is complicated by underlying liver disease and the need 43 
to avoid undue toxicity in patients with a poor prognosis. For patients with inoperable predominantly 44 
hepatic disease, locoregional therapies offer the potential for disease control, symptomatic relief and 45 
improved survival times (Cammà et al., 2002) (Bouza et al., 2009) (Memon et al., 2011). Clinical 46 
studies evaluating the use of cytotoxic chemotherapy have typically reported low response rates, with 47 
no impact on overall survival (Wrzesinski et al., 2011). The current standard of care for patients with 48 
metastatic HCC is sorafenib, an oral multi-kinase inhibitor with anti-proliferative and anti-angiogenic 49 
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properties. It confers a mean survival advantage of 3 months in comparison to best supportive care 50 
(BSC), but rarely induces radiological responses, and is associated with significant toxicity (Cheng et 51 
al., 2009) (Llovet et al., 2008).  52 
Immunotherapies are a promising class of drugs that include OV, therapeutically useful viruses that 53 
preferentially replicate in, and kill cancerous cells. Growing evidence suggests that effective oncolytic 54 
virotherapy is unlikely to be achieved merely by direct infection and cell lysis, but rather through 55 
efficient stimulation of an anti-cancer immune-response as reviewed by Melcher et al., 2011. To date, 56 
hundreds of patients with HCC have been treated using OV in phase 1 and 2 clinical trials. The 57 
emerging data is encouraging both in terms of the relatively favourable side-effect profiles and early 58 
signs of efficacy. The current lead agent, JX-594 also known as Pexa-Vec (pexastimogene 59 
devacirepvec) was granted orphan drug status in HCC by the U.S. Food and Drug Administration in 60 
2013 and by the European Medicines Agency in 2009 (France, 2013). Orphan drug designation 61 
(ODD) is approved for drugs that seek to treat rare diseases for which there may be few adequate 62 
therapies, and comes with incentives that include marketing exclusivity, grant funding for clinical 63 
trials and tax credits for clinical research expenses. Whilst these incentives assert the dominance of 64 
JX-594 in the field, they have not perturbed the translational development of other OV for HCC 65 
therapy. In addition to JX-594, three other OV have been or are currently being tested in HCC-66 
directed clinical trials, including two based on type 5 adenoviruses, dl1520 (ONYX-015) (Habib et 67 
al., 2002) and H101 (Oncorine) [NCT01869088] as well as a vesicular stomatitis virus (VSV) 68 
encoding the human interferon (IFN)-ȕgene (VSV-hIFN-ȕ [NCT01628640].  69 
This review summarises the pre-clinical and clinical progress of oncolytic virotherapy in HCC, 70 
focussing on the molecular methods employed to improve virus targeting to malignant hepatocytes, 71 
the use of virus-encoded therapeutic genes, and methods to improve viral survival. We also 72 
summarise the completed and ongoing clinical trials, routes of clinical viral delivery, and published 73 
clinical safety and efficacy data. 74 
Engineering Oncolytic Viruses for HCC Therapy 75 
Although the first wave of OV clinical trials took place in the 1950s and 1960s, it was not until the 76 
1990s that engineered OV blossomed alongside advances in DNA manipulation and molecular 77 
biology techniques.  78 
Targeting Malignant Hepatocytes 79 
The specificity of any given drug determines its side-effect profile and greatly influences its efficacy. 80 
JX-594, dl1520, H101 and VSV-hIFN-ȕ have all been engineered for pan-cancer specificity, targeting 81 
hallmark cancer characteristics, such as TP53 deletion and upregulated thymidine kinase (TK) 82 
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expression. Other engineered pan-cancer specific OV have also shown efficacy in pre-clinical HCC 83 
models, including those whose genome expression is driven by survivin, an inhibitor of apoptosis 84 
protein family that is overexpressed in the majority of HCC cases (survivin promoter-regulated 85 
oncolytic adenovirus vector carrying TP53 gene, AdSurp-P53) and human telomerase reverse 86 
transcriptase (hTERT), expressed in up to 90% of HCCs, but only some 20% of non-malignant liver 87 
cells (hTERT promoter-regulated replicative adenovirus, SG300) (Kannangai et al., 2005) (He et al., 88 
2012) (Nagao et al., 1999) (Liu et al., 2011). More recently, OV that preferentially target tumour 89 
initiating cells have been engineered, including oncolytic measles virus retargeted to CD133 positive 90 
cells (Bach et al., 2013). In the liver, CD133 expression is limited to cancerous tissue, and is 91 
associated with colony formation and high proliferative capacity (Kohga et al., 2010)  (Zhu et al., 92 
2010).   93 
In contrast to pan-cancer specific OV, numerous pre-clinical OV have been engineered to specifically 94 
target HCC (table 1). Commonly, HCC-specific viral promoters are inserted into the viral genomes 95 
that restrict the transcription of viral genes to HCC cells and hence limit the destruction of healthy 96 
cells (Ohguchi et al., 1998) (Foka et al., 2010). Viral gene expression in these systems can be further 97 
increased by the insertion of an insulator element upstream of the HCC specific promoter, to shield 98 
from viral silencers, while retaining specific gene expression in hepatoma cells (Ye et al., 2003).  99 
A further approach to specifically target malignant hepatocytes is to exploit the differential expression 100 
of micro-RNA (miRNA) transcripts; recently, a 30 miRNA signature consisting of 10 down-regulated 101 
and 20 up-regulated miRNAs was established for distinguishing HCC from non-cancerous liver 102 
tissues (Wei et al., 2013). Complementary sequences to miRNA transcripts that are specifically down-103 
regulated in HCC e.g. mir-122 and mir-KDYHEHHQLQVHUWHGLQWRWKH¶XQWUDQVODWHGUHJLRQVRI29104 
including oncolytic type 5 adenovirus and HSV (Cawood et al., 2009) (Fu et al., 2012) (Khalid 105 
Elamin Elhag, 2012). The resulting selective viral RNA degradation in normal hepatocytes led to 106 
decreased hepatotoxicity, whilst retaining anti-HCC potency in animal models.  107 
These methods are not without their problems as shown in table 1, and the protein or miRNA-binding 108 
site to be engineered into the OV genome must be chosen wisely. 109 
Enhancing Anti-Cancer Efficacy 110 
Numerous therapeutic anti-cancer genes have been engineered into oncolytic viruses in a bid to 111 
enhance efficacy. In particular, replication competent adenovirus vectors have been extensively 112 
modified and tested in pre-clinical models of HCC as illustrated in Fig. 1. The engineered therapeutic 113 
genes fall under one of two broad categories: those that modify the tumour microenvironment 114 
including stimulation of anti-HCC immune responses, and those acting directly on HCC cells to 115 
induce apoptosis and reduce cell growth and survival. In addition to the examples shown in figure 1, 116 
Downloaded from www.sgmjournals.org by
IP:  129.11.190.130
On: Mon, 29 Jun 2015 13:03:18
both oncolytic measles and Newcastle disease viruses have been engineered to express enzymes that 117 
convert the prodrug 5-fluorocytosine into the active chemotherapeutic 5-fluorouracil, enabling OV-118 
mediated targeted chemotherapy, significantly enhancing OV efficacy (Lv et al., 2013) (Lampe et al., 119 
2013). The majority of approaches to arming OV can be equally applied in the treatment of any solid 120 
malignancy. Exceptions include recombinant human erythropoietin (rhEPO), which was recently 121 
engineered into an oncolytic Lister strain Vaccinia virus (GLV-1h210) and tested in lung cancer 122 
xenografts (Nguyen et al., 2013). rhEPO is essential for erythropoiesis and significantly improves 123 
quality of life in anaemic cancer patients, but is associated with angiogenesis, limiting its use in 124 
highly vascularised tumours, such as HCC (Yasuda et al., 2003) (Crawford et al., 2002).  125 
A large body of evidence gathered both from pre-clinical and clinical studies in various cancer types 126 
points to the potential of OV to stimulate both innate and adaptive anti-cancer immune responses 127 
(Melcher et al., 2011) (Prestwich et al., 2008a) (Prestwich et al., 2009). This could also be important 128 
for OV therapy in HCC. However, the liver is an immunologically privileged organ, skewed towards 129 
an environment of immunological tolerance rather than immunity, as evidenced, for example, by 130 
reports of the acceptance of liver allografts across major histocompatibility barriers without 131 
immunosuppressive therapy (Seyfert-Margolis & Turka, 2008). This immunosuppressive 132 
microenvironment is further compounded in HCCs that frequently harbour enriched regulatory T-133 
cells, elevated immunosuppressive cytokines such as transforming growth factor (TGF)-ȕDQG134 
interleukin (IL)-10, and decreased immunostimulatory cytokines such as IL-2 and IFN-Ȗ (Shirabe et 135 
al., 2010). In addition, frequently impaired functional activities of NK cells in HCC are associated 136 
with poor prognosis (Wada et al., 1998) (Wu et al., 2013).  137 
Encouragingly, HCCs with a more favourable immune microenvironment, including NK cell 138 
accumulation are associated with improved survival, and pre-clinical evidence exists for the 139 
infiltration of HCC by NK cells following OV therapy, whilst the depletion of NK cells inhibits OV-140 
mediated anti-HCC effects (Chew et al., 2009) (Gentschev et al., 2011) (Tsuchiyama et al., 2007) 141 
(Kwon et al., 2001). Several cytokines that have the potential to stimulate anti-cancer NK cell 142 
responses have been engineered into OV; IL-12 induces the proliferation and activation of NK cells, 143 
in addition to the differentiation of naïve CD4+ T-cells into Th1 cells (Hamza et al., 2010). Similarly, 144 
chemokine (C-C motif) ligand 5 (CCL5) also drives the cytolytic activity of NK cells, and induces 145 
NK cell proliferation through T-cell mediated IL-2 secretion (Taub et al., 1995) (Maghazachi et al., 146 
1996). Whilst IL-12 and CCL5 have shown promising anti-HCC effects in pre-clinical models, others 147 
including IFN-ȕ, a powerful stimulator of NK cell activation, are currently being tested in patients 148 
with advanced HCC (NCT01628640).  149 
Key to priming successful T-cell anti-HCC responses are antigen presenting cells (APCs), of which 150 
dendritic cells (DCs) are of utmost importance. It is known that DCs from HCC patients have 151 
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significantly lower capacity to stimulate T-cells than DCs from patients with liver cirrhosis or normal 152 
controls (Ninomiya et al., 1999). Furthermore in chronic viral hepatitis, there are decreased DC liver 153 
populations and impairment in DC capacity to prime naïve T-cells, contributing to the inadequate 154 
adaptive immune responses observed (Kanto et al., 2004) (Averill et al., 2007). OV are capable of 155 
driving successful T-cell anti-cancer therapy as shown in melanoma models utilising oncolytic wild-156 
type reovirus and VSV-GFP (Prestwich et al., 2008b) (Wongthida et al., 2011). In HCC pre-clinical 157 
models, the oncolytic Vaccinia virus GLV-1h68, encoding several biomarker genes only (see table 3), 158 
has been shown to promote the intense infiltration of DCs into both HBV positive and hepatitis virus 159 
negative xenografts, whilst VSV-GFP promoted the infiltration of DCs into HCC tumours in an 160 
orthotopic immunocompetent animal model (Gentschev et al., 2011) (Shinozaki et al., 2005). 161 
Although not a prerequisite for successful T-cell therapy, the OV-mediated expression of engineered 162 
immunostimulatory genes has the potential to greatly improve efficacy. Several approaches to 163 
enhance DC maturation/activation have been tested in pre-clinical HCC models, and include arming 164 
viruses with granulocyte macrophage colony-stimulating factor (GM-CSF) or CpG-rich sequences, 165 
the latter of which has been shown to increase IFN-Ȗ and DC activation in draining lymph nodes, 166 
resulting in improved therapy against hepatoma lung metastases in comparison to the wild-type virus 167 
(Raykov et al., 2008). Other groups have shown enhanced DC and CD4+ T-cell tumour infiltration 168 
using Vaccinia viruses encoding CCL5 or a secretory bispecific T-cell engager consisting of two 169 
single- chain variable fragments specific for CD3 and the tumour cell surface antigen EphA2 (Li et 170 
al., 2011) (Yu et al., 2014).  171 
Immune cell recruitment and activation also plays a prominent role in the OV-induced disruption of 172 
tumour-associated vasculature. Indeed, inflammation-mediated disruption of vasculature is a well-173 
documented phenomenon (Bryant et al., 2005) (Lee & Slutsky, 2010). VSV infection of subcutaneous 174 
tumours resulted in transcriptional activation of the neutrophil chemoattractants CXCL1 and CXCL5, 175 
inducing tumour infiltration by neutrophils, vascular shutdown and the apoptosis of uninfected tumour 176 
cells (Breitbach et al., 2007). The depletion of neutrophils prior to VSV infection abrogated these 177 
effects. In addition to the role played by OV-induced inflammation, JX-594 has been shown to 178 
directly infect and kill tumour-associated vascular endothelial cells in mice following intravenous 179 
delivery (Breitbach et al., 2013). These findings have been confirmed in human HCC trials, 180 
demonstrating disruption of tumour perfusion following JX-594 therapy (Liu et al., 2008) (Heo et al., 181 
2011).   182 
The effects of OV on the wider HCC microenvironment is complex and has recently been reviewed 183 
elsewhere (Altomonte & Ebert, 2014). 184 
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Enhancing viral delivery and viral survival  185 
Perhaps the biggest challenge to successful oncolytic virotherapy in HCC is the ability to infect 186 
sufficient numbers of malignant hepatocytes with a sufficiently high multiplicity of infection and to 187 
maintain viral propagation. It is well established that the immune response to OV is likely to play a 188 
dual role; simultaneously clearing the virus and hence limiting efficacy, whilst at the same time 189 
becoming more activated and primed to attack malignant cells (Melcher et al., 2011). It is known that 190 
adenovirus is rapidly removed following IV delivery by Kupffer cells, liver resident macrophages, 191 
and the same may be true of other viruses (Tao et al., 2001). A number of novel methods have been 192 
employed to enhance systemic viral delivery to the desired target including Kupffer cell depletion 193 
using replication-defective adenovirus, prior to replication-competent adenovirus therapy, and 194 
warfarinisation to block coagulation factor and complement dependent binding of adenovirus to 195 
hepatocytes (Shashkova et al., 2008). Combined Kupffer cell depletion and warfarinisation resulted in 196 
decreased hepatotoxicity and increased anti-tumour potency, albeit in subcutaneous xenografts 197 
(Shashkova et al., 2008). A different approach that has been tested in pre-clinical models of HCC is to 198 
engineer OV to evade immune inactivation (table 2). These engineered OV are yet to be tested in 199 
clinical trials and it remains to be seen whether they paradoxically result in reduced immune-mediated 200 
anti-cancer efficacy. 201 
Engineered OV Tested in HCC-Directed Clinical Trials 202 
In addition to the plethora of engineered oncolytic adenoviruses, a large number of wild-type and 203 
recombinant OV have been investigated in pre-clinical models of HCC, but are yet to enter HCC-204 
directed clinical trials (table 3). Some of these viruses are clinical-grade agents that have been 205 
employed in other anti-cancer clinical trials, and are hence the more likely to proceed to HCC-206 
directed trials.  207 
The following sections describe the OV that have entered HCC-directed clinical trials to date: 208 
JX-594 209 
JX-594 was first filed for patent in 2005 by Jennerex Biotherapeutics ULC; a company that entered 210 
into a commercialization and development agreement for JX-594 with Transgene in 2010 and was 211 
later acquired by SillaJen Inc. in 2013 (Kirn, 2006) (Transgene, 2010) (Transgene, 2013a). The Wyeth 212 
strain of Vaccinia virus, that forms the backbone of JX-594 was derived from the poorly pathogenic 213 
New York City Board of Health strain. The Wyeth strain was extensively employed as a smallpox 214 
vaccine in the U.S. until routine vaccination was rescinded in 1971 (ODC, 1971). JX-594 has been 215 
genetically modified by the homologous recombination of a pSC65 plasmid with the Vaccinia virus 216 
TK gene. The plasmid sequence contains the human GM-CSF gene under the control of a synthetic 217 
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early-late promoter and the LacZ reporter gene (Mastrangelo et al., 1998). GM-CSF induces direct 218 
anti-tumour effects and importantly influences the immune system through the stimulation, 219 
recruitment and maturation of dendritic cells (Urdinguio et al., 2013) (Mach et al., 2000).  220 
The expression of TK, an enzyme of the DNA precursor pathway, is strictly regulated during the 221 
normal cellular cycle, but is much higher and permanently expressed in malignant growing cells 222 
(Hengstschläger et al., 1998). Being TK deleted, JX-594 cancer-selectivity was believed to be 223 
dependent on elevated cellular TK levels in cancers. However, recent work has shown JX-594 cancer 224 
specificity to be multi-mechanistic, with replication being dependent on epidermal growth factor 225 
receptor/Ras /mitogen-activated protein kinase pathway signalling, cancer cell resistance to type-I 226 
interferons, as well as cellular TK levels (Parato et al., 2012).  227 
VSV-hIFN-ȕ 228 
VSV is a negative-strand RNA virus that is non-pathogenic to humans. Effective immune defence to 229 
VSV is dependent on the host interferon response, with mice harbouring defective interferon systems 230 
succumbing to normally harmless VSV exposure (Durbin et al., 1996). Insertion of genes between the 231 
viral glycoprotein and polymerase genes does not affect the fitness of the resultant recombinant virus 232 
(Fernandez et al., 2002). Generation of VSV-hIFN-ȕLVDFKLHYHGE\LQVHUWLRQRIWKHKXPDQK,)1-ȕ233 
gene into the same position of the full-length viral antigenomic cDNA, pVSV-XN2, using unique 234 
restriction enzyme sites (Obuchi et al., 2003). The expression of hIFN-ȕ renders successful virus 235 
propagation dependent on defective cellular interferon response pathways, as found in many cancers 236 
(Barber, 2004). In addition, expression of hIFN-ȕLVHQYLVDJHGWRDFWLYDWH1.DQG7-cells and 237 
facilitate the maturation of DCs for immune-mediated anti-tumour therapy, as well as directly 238 
inhibiting malignant cell proliferation (Odaka et al., 2001) (Ferrantini & Belardelli, 2000) (Kadowaki 239 
et al., 2000). VSV-hIFN-ȕLVSDWHQWHGDQGEHLQJGHYHORSHGE\WKH0D\R)oundation for Medical 240 
Education and Research (Federspiel et al., 2010). 241 
dl1520 (ONYX-015) and H101 (Oncorine) 242 
The adenovirus type 5 early regions 1A (E1A) and 1B (E1B) can be exploited to engineer cancer 243 
specificity; the protein products of E1A induce cellular DNA synthesis and transformation, but trigger 244 
apoptosis mediated by the mammalian tumour cell suppressor protein p53, with a resultant reduction 245 
in the yield of progeny (Bayley & Mymryk, 1994) (Debbas & White, 1993). The 55-kDa E1B protein 246 
binds to the p53 protein and blocks p53-mediated transcriptional activation, hence limiting p53-247 
dependent cell cycle arrest and apoptosis (Sarnow et al., 1982) (Yew & Berk, 1992). Early gene-248 
therapy adenoviral type 5 vectors were modified to disable productive infection by the deletion of 249 
both E1A and E1B. These replication deficient adenovirus vectors were extensively used in cancer 250 
gene therapy trials, however evidence for efficacy was restricted due to self-limiting transgene 251 
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expression, poor target cell transduction and lack of tumour cell targeting (Vile et al., 2000). On the 252 
other hand, disabling the E1B region alone theoretically leads to selective replication in p53-deficient 253 
cells. One of the first such replication-selective type 5 adenoviruses, dl1520 has an 827-base pair 254 
deletion in the E1B region and a point mutation at codon 2022 that generates a stop codon preventing 255 
expression of a truncated protein from the deleted gene (Barker & Berk, 1987).  256 
Initial data suggested that dl1520 does indeed selectively replicate in TP53-deficient cells (Bischoff et 257 
al., 1996). However, it is now accepted that TP53 status is in fact a poor predictor of the sensitivity of 258 
tumour cells to dl1520 with tumour specificity being determined by other factors such as the 259 
inhibition of viral RNA export in non-malignant cells (Edwards et al., 2002) 2¶6KHDet al., 2004). An 260 
incomplete understanding of the mechanisms of OV cancer specificity can hamper clinical progress, 261 
as exemplified by a trial testing dl1520 in hepatobiliary cancers, where patients with HBV infections 262 
were in hindsight unnecessarily excluded due to theoretical risks that HBV protein X can inactivate 263 
p53 protein in non-malignant hepatocytes, rendering them susceptible to dl1520 productive infection 264 
(Makower et al., 2003). 265 
dl1520 was clinically developed by Onyx Pharmaceuticals under the name ONYX-015 until 2003 266 
when a promising phase 3 trial in head and neck cancer was suspended. Exclusive rights to ONYX-267 
015 were sold to Shanghai Sunway Biotech in 2005 (Investis, 2005). In the years preceding this 268 
acquisition, Shanghai Sunway Biotech was simultaneously developing H101 (Oncorine), a 269 
recombinant human adenovirus type 5 similar to ONYX-015. In November 2005, the Chinese State 270 
Food and Drug Administration approved H101 for advanced nasopharyngeal carcinoma in 271 
combination with chemotherapy (Medscape, 2005). Like dl1520, H101 is E1B gene deleted, but 272 
unlike dl1520, H101 has an additional partial E3 78.3-ȝPJHQHVHJPHQW deletion (Lu et al., 273 
2004). E3 gene products prevent T-cell and NK cell recognition of infected cells by preventing 274 
transport of MHC class I to the plasma membrane and by sequestration of MHC class I-related 275 
molecules A and B respectively (Burgert & Kvist, 1985) (McSharry et al., 2008). The partial E3 gene 276 
deletion in H101 is thought to enhance its safety profile, although this may be at the cost of decreased 277 
anti-cancer potency (Suzuki et al., 2002).  278 
Clinical Experience of Oncolytic Virus-Based Therapy in 279 
HCC 280 
To date only 4 HCC-directed clinical trials using two different OV, JX-594 and dl1520 have been 281 
undertaken and completed follow-up (table 4). Early phase trials that include a mixed population of 282 
patients with digestive tract tumours, have typically recruited very small numbers of patients with 283 
HCC, making it difficult to adequately characterise the performance of these agents (Park et al., 2008) 284 
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(Habib et al., 2001). It is also noteworthy that patients with significant chronic infections including 285 
HIV, HBV and HCV infection are frequently excluded from trials of OV that include multiple disease 286 
sites, primarily due to the perceived risk of increased adverse events (Pecora, 2002) (Vidal et al., 287 
2008). Encouragingly, at least 3 other OV trials exclusively for HCC are either underway or nearing 288 
completion (table 5). 289 
Route of Delivery 290 
The safety and efficacy of OV therapy is dependent not only on viral specifics, but also on numerous 291 
clinical considerations, including the administered dose of virus, the rate of infusion, the anatomical 292 
distribution of disease and the route of delivery.  293 
Intratumoural Injection 294 
Numerous intratumoural (ITu) therapies have been trialled in liver tumours, and it is a popular OV 295 
delivery method in HCC (see tables 4 and 5) (Venook, 2000). The advantages of the ITu route are the 296 
delivery of a high concentration of drug to the target, whilst minimising off-target side-effects, an 297 
important consideration in HCC where the background liver is frequently cirrhotic with reduced 298 
functional capacity. However, direct ITu injection carries significant risks of bleeding, infection, 299 
peritoneal tumour seeding as well as technical challenges. It is frequently impossible to inject all HCC 300 
foci, but this is not necessarily a limitation of the technique; Park et al reported that ITu injection of 301 
JX-594 led to the initial release of virus into the bloodstream, that was rapidly cleared (Park et al., 302 
2008). This was then followed by the re-emergence of circulating JX-594 days to weeks later, 303 
consistent with productive infection. In keeping with these observations, replicating JX-594 infection 304 
was found in a non-injected HCC focus metastatic to the neck following ITu liver injection (Park et 305 
al., 2008).  306 
Intravenous Injection 307 
The IV delivery of OV avoids the local injection-site side-effects associated with invasive ITu 308 
therapy. IV injection is also more likely to be acceptable to both patients and their physicians when 309 
administered at regular intervals as part of a scheduled course of treatment. Intravenous 310 
administration of JX-594 has been shown to result in viral delivery to tumours, with the key 311 
determinant of tumour infection being the administered dose (Breitbach et al., 2011). Of the patients 312 
WUHDWHGZLWKGRVHV[7 PFU kg-1 and subsequently biopsied, 87% showed JX-594 positivity in 313 
tumour by IHC or qPCR, whereas those treated with lower doses were negative. All patients on this 314 
trial had a history of vaccination with live Vaccinia virus as children, and delivery was demonstrated 315 
in a patient despite the presence of neutralizing antibodies at baseline. This finding lends support for 316 
the need to establish the maximum tolerated dose in trials of oncolytic virotherapy and to use the 317 
maximum tolerated dose in subsequent phase 2 and 3 trials. The IV route is further supported by a 318 
translational trial where oncolytic reovirus was recovered post-surgery from colorectal cancer liver 319 
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metastases following IV delivery, and shown to be capable of plaque formation ex-vivo (Adair et al., 320 
2012). In the same trial, no replicating reovirus was recovered from normal liver samples, but faint 321 
staining for reovirus sigma 3 protein was seen by IHC, supporting the notion of preferential 322 
productive infection in cancerous tissue.  323 
Several trials have employed an initial IV injection of OV followed by ITu injections. The theory 324 
behind this approach is that initial IV injection will prime an immune response that is then amplified 325 
at the target site upon further ITu injections.  326 
Hepatic Artery Injection (HAI) 327 
HAI using cytotoxic agents is in routine clinical practice for patients with HCC and warrants further 328 
investigation in oncolytic virotherapy. This is commonly employed in the form of transarterial 329 
chemoembolization (TACE), either as a palliative technique SHUVHRUDVDµEULGJLQJ¶PRGDOLW\EHIRUH330 
liver transplantation (Jelic & Sotiropoulos, 2010). The TACE principle employs HAI of cytotoxic 331 
drug combinations followed by lipiodol or degradable microsphere injection for vessel occlusion, 332 
resulting in tumour cell ischaemia and necrosis.  333 
It is debateable whether HAI enhances viral delivery to localised targets over the simpler method of 334 
ITu injection. HAI also does not prevent systemic side-effects as was significantly highlighted by the 335 
well-publicised death of the teenager Jesse Gelsinger secondary to systemic inflammatory response 336 
syndrome (SIRS) induced by the hepatic artery injection of 3.8x1013 virus particles of replication 337 
incompetent adenovirus type 5 (E1 and E4 deleted) encoding ornithine transcarbamylase cDNA 338 
(Raper et al., 2003). The strength of HAI lies in the opportunity to improve on existing locoregional 339 
therapies in combination with TACE, and encouragingly, a phase 3 trial of H101 in combination with 340 
TACE in patients with HCC is currently recruiting (table 5). Clearly, further trials testing OV by HAI 341 
are warranted and it remains to be seen which route of delivery is preferable in terms of safety, 342 
efficacy and patient acceptability.  343 
Clinical Safety Data 344 
As can be seen from table 4, both ITu and IV injections of JX-594 have been tested in patients with 345 
HCC. The most common adverse events are an influenza-like illness comprising headache, nausea, 346 
vomiting and fatigue (Park et al., 2008) (Breitbach et al., 2011) (Heo et al., 2013a). A mild fever 347 
occurs in all patients and is dose-related (Heo et al., 2013a). A maximum tolerated dose was reached 348 
at 109 PFU due to grade III hyperbilirubinaemia subsequent to transient tumour swelling inducing 349 
biliary obstruction (Park et al., 2008). Peri-tumoural oedema, induced by acute inflammation has been 350 
commonly reported in trials using OV and in fact response after initial tumour flare is a class effect of 351 
immune therapies in general (Pecora, 2002) (Senzer et al., 2009) (Wolchok et al., 2009). The absence 352 
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of substantial changes in AST and ALT suggest that direct destruction of healthy hepatocytes 353 
following JX-594 injection is mild (Park et al., 2008).  354 
Habib et al reported safety data from 10 patients with HCC treated with dl1520. Following a dose-355 
escalation study in patients with either primary or secondary liver tumours in which no maximum 356 
tolerated dose was reached, a further small HCC-directed trial was undertaken in Egypt (Habib et al., 357 
2001). In the latter study 10 patients were randomised in a 1:1 ratio to receive either a single IV dose 358 
of 3x1011 PFU of dl1520 followed by 5 ITu doses, or standard of care therapy with 95% ethanol by 359 
ITu injection (Habib et al., 2002). Of the five patients treated with dl1520, three suffered from 360 
CTCAE grade I-II fever and rigors, and 2 patients suffered from transient hypotension at the time of 361 
the infusions. Very minor changes in AST and ALT were observed for patients treated with dl1520, in 362 
comparison to the much higher levels of serum transaminases observed following ethanol treatment 363 
(Habib et al., 2002). 364 
Assessing Efficacy in OV Therapy for HCC 365 
For the approval of new anti-cancer drugs, the FDA accepts improved survival, as well as surrogate 366 
markers that predict clinical benefit.  The Response Evaluation Criteria in Solid Tumours (RECIST) 367 
use single linear summation of target lesions to define response to therapy (Therasse et al., 2000). 368 
However, the clinical benefit provided by anti-cancer therapy in HCC correlates poorly with 369 
conventional methods of response assessment (Llovet et al., 2008) (Forner et al., 2009). In 2008, the 370 
American Association for the Study of Liver Diseases (AASLD) developed a set of guidelines, termed 371 
the modified RECIST or mRECIST criteria aimed at providing a common framework for the design 372 
of clinical trials in HCC (Lencioni & Llovet, 2010). These guidelines consider estimation of the 373 
reduction in viable tumour area using contrast-enhanced radiologic imaging to be the optimal method 374 
to assess treatment response in HCC. Nonetheless, both RECIST and mRECIST criteria must be 375 
employed with caution in trials using immunotherapies; in particular, OV may cause transitory 376 
tumour-flare secondary to inflammatory cytokine release, leading to tumour enlargement and 377 
increased contrast enhancement, prior to tumour necrosis and shrinking (Senzer et al., 2009). 378 
Delaying radiologic assessment following OV therapy could potentially avoid this issue (Hales et al., 379 
2010).  380 
Clinical Evidence of Anti-Tumour Efficacy 381 
In a recent pivotal study, 30 patients with advanced HCC were randomised to low (108 PFU) or high 382 
dose (109 PFU) intratumoural JX-594 administered every 2 weeks (Heo et al., 2013a). The majority of 383 
patients in both groups had previously received locoregional therapy, but more patients in the high 384 
dose group had previously failed sorafenib therapy, a poor prognostic factor. Median overall survival 385 
was 14.1 months for the high dose arm and 6.7 months for the low dose arm. Despite the relatively 386 
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small sample size, a statistically significant survival benefit (P=0.020) was demonstrated because of 387 
the large effect size. Both doses were associated with mRECIST responses, decreased tumour 388 
perfusion and decreased tumour contrast enhancement. This is the first study to show a statistically 389 
significant benefit derived from OV therapy in patients with HCC.  390 
JX-594 has been tested as second line therapy in two phase 2 HCC trials (see table 4). In the larger of 391 
these studies (TRAVERSE), patients who had previously failed sorafenib therapy were treated with 392 
JX-594 and BSC or BSC alone (Transgene, 2013b). Sadly, the primary endpoint of improved overall 393 
survival was negative. The failure of JX-594 in the TRAVERSE trial following promising randomised 394 
dose-finding trial data remains to be fully explained. Patients recruited to the TRAVERSE trial were 395 
more likely to have sorafenib-resistant cancers. Acquired cellular resistance mechanisms to sorafenib 396 
following long-term exposure include compensatory crosstalk between PI3K/Akt and MAPK 397 
pathways, upregulation of the JAK-STAT pathway and enhanced epithelial-mesenchymal transition 398 
(Zhai & Sun, 2013). These changes could theoretically affect OV infection and anti-cancer efficacy, 399 
although recently, the modified Lister strain Vaccinia virus, GLV-1h68, was shown to effectively 400 
infect and kill sorafenib-resistant HCC cell lines (Ady et al., 2014). Alternatively, the failure of JX-401 
594 in the TRAVERSE trial could be attributed to more advanced disease in the second line setting; 402 
fitter patients carrying a smaller HCC disease burden are most likely to respond to OV therapy, as has 403 
been the experience with other immunotherapies (Coppin et al., 2005).  Furthermore, the relatively 404 
small number of patients included in phase 2 trials presents a challenge when seeking outcomes of 405 
study drug superiority over standard care. Nonetheless, Transgene recently announced a shift in 406 
strategy, moving JX-594 trials away from the second-line setting in HCC. Instead, a phase 3 trial 407 
which is expected to enrol approximately 600 patients and is anticipated to begin recruitment in 2015, 408 
will be testing whether first line IT JX-594 (weeks 0, 2 and 4) followed by sorafenib (week 6 409 
onwards) improves overall survival in comparison to sorafenib alone (Transgene, 2014).  410 
In contrast, no meaningful efficacy data can be derived from the dl1520 trial by Habib et al; one 411 
patient who received dl1520 experienced a partial response with reduction in tumour volume from 412 
306 to 22.5 cm3 associated with a concomitant decrease in AFP level from 7604 to 300 ng mL-1 413 
(Habib et al., 2002). The remaining four patients demonstrated progressive disease with an increase in 414 
both tumour volume and AFP levels. Larger randomised trials are needed to determine whether 415 
recombinant type 5 adenoviruses are efficacious in HCC. 416 
Clinical Evidence of Anti-cancer Immune Stimulation 417 
Anti-cancer immune stimulation could be at least partially responsible for the reported decreases in 418 
the size and contrast enhancement of non-injected tumours following intratumoural JX-594 injection 419 
elsewhere (Park et al., 2008) (Heo et al., 2013a). However, little ex-vivo evidence has been gathered 420 
to date from clinical trials for anti-HCC immune responses. In their randomised dose-comparison 421 
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phase 2 trial, Heo et al demonstrated HCC immune infiltration following JX-594 injection by both 422 
radiographic peripheral tumour enhancement and histologically confirmed diffuse lymphocyte 423 
infiltration from biopsied tumours (Heo et al., 2013a). In the same trial, Heo et al assessed antibody-424 
mediated complement-dependent cytotoxicity (CDC) by the addition of serum from JX-594 treated 425 
patients to HCC cell lines, resulting in cytotoxicity from 11 of the 16 subjects tested (Heo et al., 426 
2013a). Indeed, CDC could be of vital importance in OV therapy as evidenced by a recent JX-594 427 
study in patients with a variety of cancer types, where patients with the longest survival duration had 428 
the highest CDC activity (Kim et al., 2013). Evidence was also gathered for antibody development 429 
and T-cell immunity against JX-HQFRGHGSURWHLQVLQFOXGLQJȕ-galactosidase, an observation of 430 
likely importance in the elimination of virus-infected tumour cells (Heo et al., 2013a). Whilst 431 
encouraging, these results do not constitute an adaptive anti-HCC immune response. At least 6 432 
different HCC-specific tumour associated antigens (TAA) that are targeted by T-cells have been 433 
identified and future OV trials should assess whether specific T-cell responses against these antigens 434 
are induced (Breous & Thimme, 2011).  435 
Other evidence for immune stimulation is similarly encouraging, though sparse; both elevated TNF-Į436 
and IFN-ȖKDYHEHHQREVHUYHGLQWKHVHUXPRI+&&SDWLHQWVWUHDWHGZLWK-;-594 (Liu et al., 2008) 437 
(Park et al., 2008). These are likely to contribute to DC maturation, cancer growth inhibition and 438 
apoptosis. Of interest, the presence of type I interferons, powerful stimulators of NK cell activity and 439 
DC maturation, has not been reported in JX-594-treated patients, perhaps due to efficient Vaccinia 440 
virus-mediated inhibition of the interferon system (Perdiguero & Esteban, 2009). In contrast, other 441 
viruses e.g. measles, reovirus and VSV, are known to efficiently induce type I interferons, wetting the 442 
appetite for HCC clinical trials in HCC with thorough translational read-outs using such agents 443 
(Steele et al., 2011) (Diaz et al., 2007) (Donnelly et al., 2013). One potential concern is that co-444 
infection of HCV infected hepatocytes with OV will not lead to robust interferon induction due to the 445 
interferon evasion mechanisms employed by HCV. For example, HCV NS3/NS4a protease disrupts 446 
pattern recognition receptor signalling by cleaving the RIG-I and TLR3 downstream adaptors, MAVS 447 
and TRIF respectively (Foy et al., 2005) (Li et al., 2005b) (Ferreon et al., 2005). NS3/NS4A also 448 
perturbs RIG-I downstream signalling through disruption of virus-induced NF-ț%ELQGLQJWRWKH'1$449 
PRDII element, hence limiting IFN-ȕJHQHH[SUHVVLRQ (Foy et al., 2005) (Li et al., 2005c). 450 
Realistically however, the scenario of reovirus co-infection with HCV is unlikely to be a major factor 451 
in HCC patients, as the majority of patients only have detectable HCV proteins or genomes in a 452 
minority of clustered hepatocytes (Stiffler et al., 2009) A further concern is that HCV and HBV could 453 
supress OV-mediated adaptive anti-tumour immune responses, however, no clinical evidence for this 454 
yet exists, and future HCC-directed trials cannot afford to exclude the majority of HCC patients, with 455 
a viral aetiology. 456 
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Future Perspectives 457 
The clinical progress of JX-594 in HCC therapy provides much optimism in the field. This agent 458 
appears to be transcending the barrier between novel laboratory science and credible clinical therapy. 459 
From this clinical progress have come clues to support existing laboratory research into the 460 
mechanisms of OV-mediated anti-HCC efficacy including the direct, immune and anti-vascular 461 
effects. However, much remains to be discovered in terms of the differential response to OV therapy 462 
in subsets of patients, the optimal route of delivery and combinations with other anti-cancer therapies. 463 
Furthermore, biomarkers predictive of treatment response are greatly needed, as are continued efforts 464 
to establish early diagnoses of cirrhosis and HCC using technologies such as the non-invasive 465 
enhanced liver fibrosis test (Lichtinghagen et al., 2013). 466 
The combination of OV with sorafenib warrants particular mention. These drug combinations have 467 
non-overlapping toxicities, and potentially synergistic mechanisms of action, hence forming the focus 468 
of past and future trials. For JX-594, the sequence of this combination is of paramount importance; 469 
upfront JX-594 therapy is thought to induce acute vascular disruption, sensitising tumours to the anti-470 
angiogenic effects of subsequent sorafenib treatment. In murine tumour models, sequential JX-594 471 
followed by sorafenib therapy was superior to either simultaneous therapy or sorafenib followed by 472 
JX-594 (Heo et al., 2011). In vitro, sorafenib, a multi-kinase inhibitor, perturbs JX-594 productive 473 
infection of HCC cell lines, a result that can be predicted as sorafenib inhibits a wide range of cellular 474 
kinases in addition to its principal targets, whereas Vaccinia viruses are known to encode kinases, 475 
including B1R and TK that are essential for productive infection (Rempel & Traktman, 1992) (Parato 476 
et al., 2012) (Kitagawa et al., 2013). The very fact that the cancer specificity of JX-594 is partially 477 
dependent on elevated TK levels in malignant cells highlights the reliance of this OV on functional 478 
viral and cellular kinases. Hence, sequential scheduling works best for this OV, as was employed in 479 
the second line trial using JX-594 followed by sorafenib therapy, and a similar schedule is planned for 480 
the first line phase 3 trial (Heo et al., 2011) (Transgene, 2014).  481 
The combination of other OV that are less reliant on cellular kinase functions with sorafenib should 482 
form the focus of future studies. The precise scheduling should be determined by preclinical studies in 483 
immunocompetent animal models. Kottke et al., showed that tumours treated in vivo with VEGF 484 
inhibitors became highly susceptible to systemic treatment with reovirus, but only if the drugs were 485 
withdrawn 24±48 hours before virus delivery. The authors concluded that the rebound of VEGF 486 
signalling upon drug withdrawal conditions tumour-associated endothelium for productive infection 487 
of reovirus (Kottke et al., 2010).  488 
The complex immunomodulatory effects of sorafenib are also likely to be critical determinants of 489 
success. One report cited that sorafenib significantly reduced the number of NK cells and inhibited 490 
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their reactivity against tumour targets in animal models, whilst a contradictory report stated that 491 
sorafenib enhances IL-12 secretion from human liver-derived macrophages, hence activating NK cells 492 
(Sprinzl et al., 2013) (Zhang et al., 2013). The efficacy of OV in combination with sorafenib will 493 
therefore be partially dependent on the stimulation or suppression of immune responses. Sorafenib 494 
could theoretically enhance  OV therapy through a number of mechanisms including the synergistic 495 
activation of NK cells, and inhibition of the OV-directed humoral response, thus enhancing IV 496 
delivery, as has been the experience with chemotherapy (Lolkema et al., 2011). Alternatively, 497 
sorafenib-induced immunosuppression could limit the immune-mediated efficacy of OV, whilst 498 
immune stimulation could limit virus propagation, both resulting in reduced efficacy. Orthotopic 499 
immunocompetent animal models could begin to answer these questions, but the lack of concordance 500 
between animal models and human research highlights the need to pursue early phase clinical trials 501 
using sorafenib-OV combinations.  502 
In addition to sorafenib, numerous successful preclinical  studies have been conducted, using  OV in 503 
combination with cytotoxic agents, radiotherapy and targeted biotherapies including other pre-clinical 504 
OV (Mao et al., 2009) (Zheng et al., 2009) (Chung et al., 2002). More recently, antibodies targeting 505 
the immune checkpoint molecules, CTLA-4 and PD-1/PD-L1 have been tested in early-phase HCC-506 
directed clinical trials (Sangro et al., 2013a) (Sangro et al., 2013b). CTLA-4 is expressed on T-cells 507 
and inhibits T-cell activation, whilst PD-1/PD-L1 interactions limit the activation of NK, B- and T-508 
cells (Pardoll, 2012). Combinations of OV with immune checkpoint inhibitors are being explored in 509 
solid and haematological malignancies and should also be tested in HCC, with the premise that OV-510 
mediated tumour vaccination, followed by immune activation through checkpoint inhibition may 511 
prove highly beneficial (Engeland et al., 2014) (Minev et al., 2014). As with all combination 512 
regimens, overlapping side effects are of concern, especially severe immune-related toxicity. HCC 513 
therapy provides the opportunity to limit systemic side-effects by HAI, a delivery method that is 514 
likely to become increasingly important in future trials. 515 
Taking these combinations one step further, future studies should assess the efficacy of OV carrying 516 
cDNA libraries, in combination with checkpoint inhibitors. Effective cancer immunotherapy requires 517 
the release of TAA in the context of potent immune activation. Kottke et al., showed that a cDNA 518 
library of normal tissue, expressed from oncolytic VSV, acting as an immune adjuvant, cured 519 
established tumours of the same histological type from which the cDNA library was derived (Kottke 520 
et al., 2011). In HCC therapy, such broad antigenic stimulation can potentially lead to the attack of 521 
healthy hepatocytes. This problem can be avoided by engineering OV to express specific TAA 522 
including AFP, EpCAM and SSX-2. Clues to indicate the likely efficacy of the latter approach can be 523 
found in patients with HCC who have a better prognosis, associated with the expression of such TAA 524 
(Liang et al., 2013). Unleashing specific T-cell responses against OV-expressed TAA through 525 
combination with checkpoint inhibitors could prove to be a very valuable strategy. 526 
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Other than JX-594, a large number of clinically active and pre-clinical oncolytic viruses have been 527 
tested in HCC models, yet precious few of these agents have progressed into HCC-directed clinical 528 
trials. As in other fields, OV laboratory science races well ahead of clinical practice, and in this 529 
respect, anti-HCC oncolytic virotherapy is no different. The potential exists for the medicines 530 
regulatory authorities to approve multiple efficacious OV in HCC clinical practice, paving the way for 531 
stratified therapy. In order to realise this potential and reap the rewards, we must first push these pre-532 
clinical agents into the clinic.  533 
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Table 1 ± HCC-specific oncolytic viruses; mechanisms of targeting  
Targeting 
principle 
Example Description Issues  Reference 
Liver specific viral 
promoter 
Transthyretin-
promoter 
driven 
adenovirus 
Transthyretin is a thyroid 
hormone transport protein, 
secreted into serum by 
hepatocytes. 
Requires additional cancer specificity (Hsieh et 
al., 2009) 
HCC specific viral 
promoter 
AFP-
promoter-
driven 
adenovirus 
AFP is produced in high levels 
from the foetal liver and yolk sac, 
but not normally in adults. 
AFP is frequently only expressed in a sparse 
population of HCC cells, and can also be 
expressed from non-malignant hepatocytes in 
chronic hepatitis and cirrhosis (Ohguchi et 
al., 1998) (Johnson, 2001). 
(Zhang et 
al., 2012) 
Enzyme-activated 
viral protein 
MMP-
activated 
MVF protein   
MMP substrate site is inserted 
into MVF.   
Efficacy dependent on tumour MMP 
expression.  
Could have broader cancer specificity 
(Muhleba
ch et al., 
2010) 
miRNA mediated 
control of virus 
gene expression in 
normal liver cells 
mir-122 
regulated 
adenovirus 
mir-122 binding sites inserted 
LQWRWKH¶XQWUDQVODWHGUHJLRQRI
an adenovirus type 5 E1A-
luciferase transcription cassette. 
mir-122 expression is preserved in HCV-
induced HCC, potentially rendering mir-122 
regulated adenovirus ineffective in this subset 
of patients (Varnholt et al., 2008). 
(Cawood 
et al., 
2009) 
AFP (alpha fetoprotein); MMP (membrane metalloproteinase); MVF (Measles virus fusion); miRNA (micro-RNA) 
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Figure 1 ± Therapeutic gene products expressed by engineered replication-competent adenoviruses and tested in pre-
clinical models of HCC. Infection of a malignant hepatocyte (illustrated by the large blue rectangular cell) by replication 
competent adenovirus results in the expression of engineered therapeutic genes. Suppressor of cytokine signalling (SOCS)-1 
and SOCS3 inhibit JAK phosphorylation of STAT, thus attenuating cytokine signal transduction and suppressing tumour 
growth (Wei et al., 2011) (Liu et al., 2013). Tumour suppressor in lung cancer 1 (TSLC1) is a cell adhesion molecule whose 
overexpression inhibits cell growth and migration, and induces apoptosis (He et al., 2012). Numerous engineered genes enhance 
apoptosis: Melanoma differentiation associated gene (mda)-7/IL-24 binding to its receptor triggers mitochondrial dysfunction 
and apoptosis, whilst receptor-independent tumour suppression is achieved via the induction of sustained ER stress (Xiao et al., 
2010).The hepatocellular carcinoma suppressor 1 (HCCS1) gene product activates the mitochondrial apoptotic pathway by 
inducing lysosomal protease efflux (Gan et al., 2008) (Zhang et al., 2008). SMAC (second mitochondria-derived activator of 
caspase) inhibits the activity of XIAP, a potent inhibitor of caspase activation that prevents apoptosis (Pan et al., 2007) (Pei et 
al., 2004). XIAP protein translation can also be knocked down using targeted short hairpin RNA (shRNA), sensitizing cells to 
pro-apoptotic signals such as tumour necrosis factor-related apoptosis inducing ligand (TRAIL) (Ye et al., 2005) (Pan et al., 
2008). Other OV-encoded  therapeutic proteins that act directly on malignant cells are the pro-apoptotic apoptin and the 
sodium-iodide symporter (NIS), a transmembrane glycoprotein, which transports out two sodium cations in return for one 
iodide anion. NIS proteins allow the intracellular concentration of radioactive iodide, inducing apoptosis (Zhang et al., 2012) 
(Grunwald et al., 2013). Several OV-encoded therapeutic proteins are secreted for paracrine effects on other cells within the 
tumour microenvironment; IL-12 drives the activation/differentiation of NK and T-cells, whilst the C-C chemokine ligand 5 
(CCL5) induces NK cell activation and T-cell chemotaxis (Yang et al., 2012) (Li et al., 2013). Secreted endostatin acts on 
endothelial cells to inhibit migration and proliferation, and to induce apoptosis (Li et al., 2005a).  
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Table 2 ± Engineering OV to enhance delivery and survival in pre-clinical HCC models 
Mechanism Description Potential advantages Reference 
Viral surface 
modification using 
polymers 
Arginine-grafted bioreducible polymer or 
high molecular weight polyethylene glycol 
chemically conjugated to oncolytic 
adenovirus surface 
Reduced hepatocyte infection and 
liver toxicity 
Reduced neutralisation by antibodies 
(Kim et al., 
2011) 
(Doronin et 
al., 2009) 
Virus-mediated 
inhibition of NK 
and NKT cells 
VSV expressing a protein from human 
cytomegalovirus known to downregulate 
CD155. 
Reduced NK and NKT cell 
recruitment to the site of viral 
infection, reducing virus inactivation 
(Altomonte 
et al., 2009) 
Virus-mediated 
expression of 
chemokine-binding 
proteins 
Recombinant VSV expressing high affinity 
chemokine-binding proteins; M3, from 
murine gammaherpesvirus-68, or equine 
herpes virus-1 glycoprotein G 
Reduced neutrophil, NK and NKT 
cell recruitment to the site of viral 
infection, enhancing virus titres. 
(Wu et al., 
2008) 
(Altomonte 
et al., 2008) 
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Table 3 ± OV Tested in Pre-clinical Models of HCC 
Virus species Name Modifications Assessed in Clinical Trials? Pre-clinical HCC Model Reference 
Parvovirus H-1 H-1PV Wild-type Yes, glioma Cell lines (Moehler et al., 2001) 
 
 
HSV-1 
 
 
G207 Deletion of both ICP34.5 neurovirulence genes & inactivation of ICP6 (ribonucleotide 
reductase) by insertion of the E.coli lacZ gene. Yes; glioma 
Cell lines and 
subcutaneous 
murine xenografts 
(Song et al., 2006)       
(Xue et al., 2005) 
Cgal-Luc DeULYHGE\UHSDLURI,&3SRVLWLYHDQGQHJDWLYHUHJXODWLRQRIYLUXVJHQRPHIURP&JDOǻ
virus, insertion of the LacZ gene into IGR54 and luciferase gene into IGR20. No Subcutaneous 
murine xenografts 
 
(Argnani et al., 
2011) 
 H6-Luc Derived from the H6 mutant; syncytium forming (Syn
-), benzhydrazone (glycosylation 
inhibitor) resistant. Luciferase cassette inserted into IGR20. 
The closely related HF10 mutant 
has been tested in multiple solid 
tumours 
G92A ICP4 regulated by the albumin enhancer/promoter, mutated US3 gene (inhibitor of virus-induced apoptosis), disrupted thymidine kinase gene and insertion of the E.coli lacZ gene.  No 
Orthotopic murine 
xenografts 
 
(Chung et al., 2006) 
 hrR3 ICP6 LacZ insertion mutant. No 
Blue tongue 
virus 
BTV-10 Wild-type, cell-culture adapted  No Hep3B cell line (Hu et al., 2008)  
BTV-HC3 Wild-type, cell-culture adapted No Cell lines (Chen et al., 2007) 
Measles virus 
(Edmonston) 
MV-CEA Expresses extracellular domain of the human carcinoembryonic antigen (CEA) Yes, glioma and ovarian cancer Cell lines and 
subcutaneous 
murine xenografts 
(Blechacz et al., 
2006) MV-NIS Expresses the human sodium iodide symporter (hNIS) Yes, myeloma and multiple solid tumours 
MV-GFP 
Expresses green fluorescence protein. Human bone marrow-derived mesenchymal stem 
cells were infected with MV-GFP and systemically delivered in passively-immunised 
mice. 
No 
Orthotopic patient-
derived HCC tissue 
xenografts 
(Ong et al., 2013) 
Newcastle 
Disease Virus 
 
NDFLtag-
EGFP 
Derived from the wild-type LaSota vaccine strain. Carrying enhanced green fluorescence 
protein. No Human and murine hepatic stellate cells 
 
(Li et al., 2009) 
 NDV-
Italien Wild-type No 
rNDV/F3a
a(L289A) L289A mutation within the F (fusion) glycoprotein No 
Immunocompetent 
orthotopic murine 
model 
(Altomonte et al., 
2010) 
NDV/Anh
-EGFP Derived from the wild-type Anhinga strain. Carrying enhanced green fluorescence protein. No 
Cell lines and 
subcutaneous 
immunocompetent 
murine model 
(Wu et al., 2014) 
Vaccinia 
 
GLV-
1h68 
Derived from the Lister strain and carries three gene cassettes: a Renilla luciferase-GFP 
(RUC-GFP) fusion cassette at the F14.5L locus, a reverse inserted human transferrin 
UHFHSWRUDQGȕ-galactosidase FDVVHWWHDWWKH-5ORFXVHQFRGHVWK\PLGLQHNLQDVHDQGDȕ-
glucuronidase cassette at the A56R locus (encoding hemagglutinin). 
Yes, multiple solid tumours 
Cell lines and 
murine xenografts 
(Gentschev et al., 
2011) 
Sorafenib-resistant 
cell lines (Ady et al., 2014) 
JX963 Western reserve expressing GM-CSF, with double deleted thymidine kinase and vaccinia growth factor genes.  
The closely related vvDD-CDSR 
expressing cytosine deaminase 
and somatostatin receptor is being 
tested in solid tumours 
Orthotopic 
immunocompetent 
rabbit model 
(Lee et al., 2009) 
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Table 4 ± Completed HCC-directed clinical trials using oncolytic viruses. Searches were performed on ClinicalTrials.gov, Current Controlled Trials, EU Clinical Trials Register and medline. 
Virus Phase  No of  
patients 
Route Delivered  
dose 
Study Design Anti-Cancer Effect Grade III or IV  
Adverse Events 
Reference 
JX-594 2 25 IV followed 
by ITu 
1x109 PFU Single treatment group. IV day 1, ITu 
days 8 and 22, sorafenib day 25 
mRECIST disease control rate 62% for JX-594 
and 59% after initiation of sorafenib 
Not available (Heo et al., 
2013b) 
JX-594 2 30 ITu 1x108 or 
1x109 PFU 
Randomised comparison between low 
and high dose JX-594 
OS 14.1 months in high dose group Vs 6.7 
months in low dose group (P=0.020) 
Lymphopaenia, 
pyrexia 
hyperbilirubinaemia 
(Heo et al., 
2013a) 
JX-594 2* 120 IV followed 
by ITu 
1x109 PFU JX-594 plus BSC or BSC only. IV 
day 1 followed by five ITu treatments 
No significant overall survival advantage Not available (Transgene, 
2013b) 
Ad5 dl1520 2 10 IV followed 
by ITu 
3x1011 PFU Randomised comparison between PEI 
and Ad5 dl1520 
1 patient had PR by RECIST and 4 had PD None (Habib et al., 
2002) 
PEI (percutaneous ethanol injection); BSC (best supportive care); IV (intravenous); ITu (intratumoural); OS (overall survival); PFU (plaque forming units); PR (partial response); PD (progressive disease);  
RECIST(Response Evaluation Criteria in Solid Tumours); mRECIST (modified RECIST); * TRAVERSE trial 
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Table 5 ± Ongoing HCC-directed clinical trials using oncolytic viruses. Searches were performed on ClinicalTrials.gov, Current Controlled Trials and EU Clinical Trials Register. 
Virus Phase  No of patients Route Study Design Primary objective(s) Progress 
Trial 
identifier 
JX-594 2 21 IV Single treatment group 5 x weekly infusions Tumour response Enrolment completed NCT01636284 
H101 recombinant human  
adenovirus type 5 
3 120 HAI Randomisation to adenovirus and TACE or  
TACE only 
Overall survival Recruiting NCT01869088 
VSV-hIFN-ȕ 1 48 ITu Modified "3+3" Fibonacci dose escalation Maximum tolerated dose Recruiting NCT01628640 
HAI (hepatic artery injection); TACE (trans-arterial chemo-embolization);  
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IL12  
binding  
to IL12R 
Differentiation 
& activation 
Activation 
Mda-7/IL-24 
binding to 
IL-20R1/R2 or 
IL-22R1/IL-20R2    
TRAIL 
binding to  
TRAIL-Rs 
STAT signal 
activation 
shRNA targeted 
to XIAP mRNA 
Apoptin  
multi-mechanistic  
induction of apoptosis 
Apoptosis Cell growth  
& survival 
Cell migration 
Apoptosome 
formation 
XIAP  
blocks 
Caspase-9  
Activation 
Procaspase-9 
Caspase-9 
SMAC  
inhibits   
XIAP 
Mitochondrial  
dysfunction 
Virus-encoded gene products 
TSLC1 
cell adhesion 
molecule 
HCCS1  
Induces 
lysosomal 
protease  
efflux 
Endostatin 
binding to 
ɲ5ɴ1 integrin 
Inhibition  
of cell 
migration, 
proliferation 
and 
induction 
of  
apoptosis 
 
Secretion of  
virus-encoded 
gene products 
for autocrine 
and paracrine 
signalling  
Mda-7/IL-24 
induction of  
ER-stress 
Secretory  
pathway 
Cytokine  
binding to  
receptor 
SOCS1/SOCS3 
inhibit Jak-STAT 
signalling 
Chemotaxis 
T-cell 
NK-cell 
CCL5 
binding  
to CCLRs 
CCL5 
binding  
to CCLRs 
Tumour 
endothelial 
cell 
Sodium-iodide symporter 
Concentrates intravenously- 
administered radioiodine (131I) 
)LJXUH
&OLFNKHUHWRGRZQORDG)LJXUH)LJXUHSSW[
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